Regulation Of Antigen-Presenting Machinery In Melanoma After Plasma Treatment

Publication date: February 2018 Source:Clinical Plasma Medicine, Volume 9, Supplement Author(s): Ramona Clemen, Thomas von Woedtke, Sander Bekeschus Cold physical plasmas have been shown to eliminate multiple types of cancers in vitro and in vivo [1] Although being multi-component systems, evidence suggest plasmas to be active primarily via release of a plethora of reactive oxygen and nitrogen species (ROS/RNS). These species not only damage cells via oxidation of proteins and lipids but also trigger signaling cascades via redox relays. This redox signaling is vital for a number of processes, e.g. the formation and loading of major histocompatibility class I complexes (MHC-I). Once loaded with peptides and translocated to the cell surface, MHC-I molecules are recognized by cytotoxic T lymphocytes. In cancer, high numbers of these lymphocytes often correlate with a good prognosis due to their ability to specifically recognize and kill tumor cells. Understanding whether and how MHCI loading and expression is regulated via exogenous oxidants such as produced by cold plasmas is key to delineate possible immune-modulating effects of plasmas in onco-therapy. Intracellular proteins get degraded to peptides by the proteasome before they get transported to the endoplasmatic reticulum by antigen peptide transporter TAP1 and TAP2. In endoplasmatic reticulum the peptides get associated with MHC-class I molecules via a number of proteins, such as Tapasin, ERp57 and PDI [2, 3]. Histon...
Source: Clinical Plasma Medicine - Category: Research Source Type: research